Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • VIP Gloves (VIP) will begin marketing its nitrile glove products in the US, after receiving approval from the Food and Drug Administration
  • The gloves supplier says it received confirmation in recent days that it’s successfully registered on the FDA Industry Systems
  • VIP will now begin marketing its gloves in the “lucrative” US market, with plans in motion to begin selling the gloves in Australia as well
  • Currently the business is awaiting a response from Australia’s drug watchdog about its application to market the gloves
  • VIP Gloves are trading up 10.3 per cent at 4.3 cents each

VIP Gloves (VIP) will begin marketing its nitrile glove products in the US, after receiving approval from the food and drug administration.

The gloves supplier said it received confirmation in recent days that it has been successfully registered on the FDA Industry Systems.

Now the registration is official, VIP will begin marketing its nitrile gloves in the “lucrative” North American market.

In a statement, the company said significant efforts were underway to make inroads into the new market and expand its geographical reach.

VIP also has plans in motion to begin selling its nitrile gloves in Australia, having made an application to the country’s drug watchdog.

The Therapeutic Goods Association was still reviewing VIP’s application, but the company said both new markets would provide it a platform to launch its own glove brand.

VIP said the US and Australian markets would also support the additional production capacity coming online.

The supplier’s nitrile gloves are already being sold into the UK and European markets, under VIP’s CE EU Examination Certificate.

Shares in VIP Gloves were trading up 10.3 per cent at 4.3 cents per share at 2:02 pm AEST.

VIP by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.